ALCIDION

23 July 2026

Australian Securities Exchange
39 Martin Place
Sydney NSW 2000

Q4 FY26 Quarterly Activities Report

Melbourne, Victoria | Alcidion Group Limited (ASX:ALC) ('**Alcidion'** or the '**Company**') has today released its Appendix 4C and Quarterly Activities Report for the quarter ended 30 June 2026 (Q4 FY26).

Highlights:

- Q4 FY26 positive operating cashflow a record $7.7M, driven by quarterly cash receipts of $24.6M
- FY26 positive operating cashflow of $6.8M, up 19% on FY25, with full year cash receipts of $56.1M
- Q4 new TCV sales and renewals of $43.2M, including:
  - ~$35.0M, 7-year contract with University Hospital Sussex (UH Sussex) for their new Electronic Patient Record (EPR)
  - 4-year (plus one) contract extension with Western Health for continued use of Miya Precision and expansion into additional beds
- Completed the acquisition of Kyra flow products from Telstra Health; cementing Alcidion's position as the leading provider of patient flow solutions in ANZ
- Cash balance of $20.6M and no debt as of 30 June 2026
  - Includes the net completion payment to Telstra Health of $1.5M on 29 June 2026, comprising $3.0M purchase price less net debt and working capital adjustments
- High confidence of delivering FY26 financial guidance, with
  - Unaudited revenue at ~$51.6M, an increase of 27% on prior year; and
  - EBITDA in excess of $5.0M

Alcidion CEO and Managing Director, Kate Quirke said: "Q4 was a very positive period for Alcidion and closed out a record FY26 year for the business across several key metrics."

"From a financial perspective we delivered record Q4 positive operating cashflow resulting in FY26 positive operating cashflow of $6.8M. This highlights our strong EBITDA to cashflow conversion, a consistent highlight of the Alcidion business, and builds upon our cash balance for future growth opportunities.

"In May, we signed UH Sussex for a seven-year contract for the deployment of Miya Precision. This contract further expands our relationship with UH Sussex where our Observations and Assessments (Patientrack) module of Miya Precision has been deployed for many years. During Q4, we received a $10.6M payment relating to the upfront capital licence fee. UH Sussex is our third EPR deployment in the UK and will be the largest trust to deploy Miya Precision for full EPR capabilities."

"During the period, we extended our long-standing relationship with Western Health, one of Victoria's largest public health networks, who utilise Miya Precision's patient flow, access and command modules. This is the fifth contract renewal with Western Health in the past 20 years and highlights our ability to add value and interoperate with large-scale EPR vendors. Western Health serves as a prime example of how the embedded nature of our software leads to long-standing customer relationships underpinned by our ability to solve complex customer challenges."

“On 29 June, we completed the acquisition of the Kyra flow products from Telstra Health. This was a strategic acquisition for Alcidion, adding 31 new customers (33 in total) across the ANZ region with a particularly strong presence in Queensland, a previously underserviced market for Alcidion. Based on their FY26 forecast EBITDA of $1.1M, we acquired the business on an upfront EBITDA multiple of approximately 2.7x, a valuation immediately accretive for our shareholders. Over time, there is an ability to create future opportunities for Miya Precision with the Kyra customers coupled with the potential for cost synergies once the businesses have been fully integrated.”

“One of Alcidion’s major strengths is our ability to seamlessly implement our solutions in an efficient and effective manner. This was recently validated by the Phase 1 ‘go-live’ of our Miya Precision EPR solution at North Cumbria, an implementation completed on-time and without incident, culminating in a major digital milestone for the Trust. As new customers seek validation and referenceabilty as part of new procurements, this forms an exciting milestone for the Alcidion business.”

“These operational milestones continue to create new opportunities for Alcidion within established ANZ and UK markets, enabling us to further expand our position as one of the leading providers of modern and modular enterprise solutions to acute healthcare organisations.”

Financial Update

Alcidion signed Q4 new sales and renewals of $43.2M (including $35.0M UH Sussex contract) of which approximately 89% is recurring product revenue and 11% is non-recurring services (product implementation) revenue.

Cash receipts from customers in Q4 were $24.6M, which includes the $10.6M payment from UH Sussex for the upfront capital licence, with record Q4 positive operating cashflow of $7.7M. This resulted in a FY26 positive operating cashflow of $6.8M, an improvement of $1.1M (or 19%) compared to FY25.

Product manufacturing and operating costs were $4.1M. As expected, and similar to Q3, this was higher than prior years as it reflects payments for the upfront licence component for third-party partner products associated with the recently won UH Sussex EPR contract.

Staff cash costs increased slightly in Q4, a result of the advanced payment of 50% of the FY26 short-term incentives (STI) which were achieved during the year. The balance of these STI payments will be made in Q1 FY27.

Included within investing cashflow activities is the net completion payment of $1.5M for the acquisition of the Kyra flow products. This payment reflects the upfront consideration of $3.0M less completion adjustments for a cash free, debt free transaction.



Payments made to related parties and their associates totalled $0.38M for the quarter, as noted in item 6 of the Company's Appendix 4C. These payments relate solely to Directors' remuneration.

Outlook

Alcidion reconfirms, with a high degree of confidence, its FY26 financial guidance with:

- Revenue expected to be ~$51.6M (subject to audit), an increase of 27% on the prior year; and
- EBITDA to exceed $5.0M.

Alcidion enters FY27 with strong momentum across all its existing markets and continues to progress several opportunities whilst maintaining a significant book of implementation revenue associated with deployments for Leidos, North Cumbria and UH Sussex.

The Company will provide a detailed update (including FY27 contracted revenue) as part of the full year FY26 results which are scheduled to be released to the ASX during the second half of August.

Investor Webcast

Alcidion Group Managing Director Kate Quirke will host a webcast with investors via Zoom on Thursday, 23 July 2026 at 11:00am Australian Eastern Standard Time (AEST).

To register for the webcast, please follow this link:

https://us02web.zoom.us/webinar/register/WN_um5rbneVTaCA5KL1V3Wgbw

Registered participants will receive an email containing the Zoom access link and phone dial-in details.

ENDS

Authorised for ASX release by the Board of Directors of Alcidion Group Limited

For further information, please contact:

Investor Relations
investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver clinical decision support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across three established markets — Australia, New Zealand and the United Kingdom — serving hospitals and healthcare organisations at scale, with further geographical expansion planned.

With over 25 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ALCIDION GROUP LIMITED

ABN	Quarter ended ("current quarter")
77 143 142 410	30 June 2026

Consolidated statement of cash flows			Current quarter $A'000	Year to date (12 months) $A'000
1.	**Cash flows from operating activities**			
1.1	Receipts from customers		24,555	56,060
1.2	Payments for			
	(a)	research and development	-	-
	(b)	product manufacturing and operating costs	(4,133)	(9,914)
	(c)	advertising and marketing	(553)	(1,211)
	(d)	leased assets	-	-
	(e)	staff costs	(7,074)	(26,587)
	(f)	administration and corporate costs	(1,413)	(5,467)
1.3	Dividends received (see note 3)		-	-
1.4	Interest received		36	160
1.5	Interest and other costs of finance paid		(11)	(57)
1.6	Income taxes paid		-	-
1.7	Government grants and tax incentives		-	-
1.8	Other – GST/VAT received/(paid)		(3,673)	(6,139)
1.9	**Net cash from / (used in) operating activities**		**7,734**	**6,845**

2.	**Cash flows from investing activities**			
2.1	Payments to acquire or for:			
	(g)	entities	-	-
	(h)	businesses	(1,475)	(1,475)
	(i)	property, plant and equipment	(126)	(226)
	(j)	investments	-	-
	(k)	intellectual property	-	-
	(l)	other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(1,601)**	**(1,701)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payment for principal portion of lease liabilities)	(252)	(800)
3.10	**Net cash from / (used in) financing activities**	**(252)**	**(800)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	15,105	17,697
4.2	Net cash from / (used in) operating activities (item 1.9 above)	7,734	6,845
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,601)	(1,701)

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(252)	(800)
4.5	Effect of movement in exchange rates on cash held	(344)	(1,399)
4.6	**Cash and cash equivalents at end of period**	**20,642**	**20,642**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	20,197	14,658
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (TDs)	445	447
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**20,642**	**15,105**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	375
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	150	10
7.4	**Total financing facilities**	**150**	**10**

7.5	**Unused financing facilities available at quarter end**	**140**
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	
	WBC corporate credit card facility secured against cash deposits; interest charged at 14.25% on overdue accounts	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	7,734
8.2	Cash and cash equivalents at quarter end (item 4.6)	20,642
8.3	Unused finance facilities available at quarter end (item 7.5)	140
8.4	Total available funding (item 8.2 + item 8.3)	20,782
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**N/A**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: **N/A**

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: **N/A**

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: **N/A**

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 23 July 2026

Authorised by: The Board of Directors

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.